{
  "docId": "019de071-94a0-75ef-b86b-e4894fa7dc1d",
  "docSlug": "8b4d61768a47893d5f24ee0f1f9ae717",
  "documentTitle": "argenx SE | Results Presentation Deck | 20 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 20,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a Venn diagram-like visual to group strategic pillars, though the lines to the bullet points are loose.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de071-94a0-75ef-b86b-e4894fa7dc1d/19",
  "deckHref": "/decks/019de071-94a0-75ef-b86b-e4894fa7dc1d",
  "deckJsonHref": "/decks/019de071-94a0-75ef-b86b-e4894fa7dc1d.json",
  "deckAnchorHref": "/decks/019de071-94a0-75ef-b86b-e4894fa7dc1d#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.35,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Three overlapping circles representing Patients, Pipeline, and Science.",
      "attrs": null,
      "subkind": "venn",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a60c469b-66d4-41af-b840-508701035be4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.5,
        "x": 0.45,
        "y": 0.15
      },
      "kind": "list",
      "text": "Global launch preparations underway in U.S., Japan and EU; Efgartigimod proof-of-concept in 4/4 indications with ambition to be in 15 by 2025; Growing neuromuscular, hematology and skin commercial franchises; ARGX-117: second pipeline-in-a-product opportunity; ARGX-119: next asset from Immunology Innovation Program; Strong partnerships in place for additional value creation; Pro-forma cash position of $2.5B as of 3Q21",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "379d8433-1626-41a6-bea2-3d8cc4cbd0ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.25,
        "y": 0.92
      },
      "kind": "paragraph",
      "text": "We believe the future belongs to those who collaborate best",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e94a179-b49e-48ea-a82a-48b55b686331",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Building a Leading Immunology Company",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc062575-ba3a-4828-977e-131f2c5ba52f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}